104 related articles for article (PubMed ID: 17460030)
1. Mutation of a single residue (K262R) in P450 2B6 leads to loss of mechanism-based inactivation by phencyclidine.
Shebley M; Hollenberg PF
Drug Metab Dispos; 2007 Aug; 35(8):1365-71. PubMed ID: 17460030
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine.
Jushchyshyn MI; Wahlstrom JL; Hollenberg PF; Wienkers LC
Drug Metab Dispos; 2006 Sep; 34(9):1523-9. PubMed ID: 16782764
[TBL] [Abstract][Full Text] [Related]
3. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation.
Bumpus NN; Sridar C; Kent UM; Hollenberg PF
Drug Metab Dispos; 2005 Jun; 33(6):795-802. PubMed ID: 15769884
[TBL] [Abstract][Full Text] [Related]
4. Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate.
Driscoll JP; Kornecki K; Wolkowski JP; Chupak L; Kalgutkar AS; O'Donnell JP
Chem Res Toxicol; 2007 Oct; 20(10):1488-97. PubMed ID: 17892269
[TBL] [Abstract][Full Text] [Related]
5. The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine.
Jushchyshyn MI; Kent UM; Hollenberg PF
Drug Metab Dispos; 2003 Jan; 31(1):46-52. PubMed ID: 12485952
[TBL] [Abstract][Full Text] [Related]
6. Selective pathways for the metabolism of phencyclidine by cytochrome p450 2b enzymes: identification of electrophilic metabolites, glutathione, and N-acetyl cysteine adducts.
Shebley M; Jushchyshyn MI; Hollenberg PF
Drug Metab Dispos; 2006 Mar; 34(3):375-83. PubMed ID: 16326815
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity.
Bumpus NN; Hollenberg PF
Mol Pharmacol; 2008 Oct; 74(4):990-9. PubMed ID: 18621926
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane.
Chun J; Kent UM; Moss RM; Sayre LM; Hollenberg PF
Drug Metab Dispos; 2000 Aug; 28(8):905-11. PubMed ID: 10901699
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling.
Shebley M; Kent UM; Ballou DP; Hollenberg PF
Drug Metab Dispos; 2009 Apr; 37(4):745-52. PubMed ID: 19144770
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms.
Bumpus NN; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2006 Jul; 318(1):345-51. PubMed ID: 16611850
[TBL] [Abstract][Full Text] [Related]
11. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2005 Apr; 313(1):154-64. PubMed ID: 15608076
[TBL] [Abstract][Full Text] [Related]
12. Metabolic inactivation of cytochrome P4502B1 by phencyclidine: immunochemical and radiochemical analyses of the protective effects of glutathione.
Sharma U; Roberts ES; Kent UM; Owens SM; Hollenberg PF
Drug Metab Dispos; 1997 Feb; 25(2):243-50. PubMed ID: 9029055
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by n-propylxanthate.
Kent UM; Yanev S; Hollenberg PF
Chem Res Toxicol; 1999 Apr; 12(4):317-22. PubMed ID: 10207119
[TBL] [Abstract][Full Text] [Related]
14. Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.
Talakad JC; Kumar S; Halpert JR
Drug Metab Dispos; 2009 Mar; 37(3):644-50. PubMed ID: 19074527
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship and elucidation of the determinant factor(s) responsible for the mechanism-based inactivation of cytochrome P450 2B6 by substituted phenyl diaziridines.
Kobayashi Y; Sridar C; Kent UM; Puppali SG; Rimoldi JM; Zhang H; Waskell L; Hollenberg PF
Drug Metab Dispos; 2006 Dec; 34(12):2102-10. PubMed ID: 16997911
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of bergamottin by cytochromes P450 2B6 and 3A5.
Kent UM; Lin HL; Noon KR; Harris DL; Hollenberg PF
J Pharmacol Exp Ther; 2006 Sep; 318(3):992-1005. PubMed ID: 16785317
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion.
Crowley JR; Hollenberg PF
Drug Metab Dispos; 1995 Aug; 23(8):786-93. PubMed ID: 7493543
[TBL] [Abstract][Full Text] [Related]
18. Modification of serine 360 by a reactive intermediate of 17-alpha-ethynylestradiol results in mechanism-based inactivation of cytochrome P450s 2B1 and 2B6.
Kent UM; Sridar C; Spahlinger G; Hollenberg PF
Chem Res Toxicol; 2008 Oct; 21(10):1956-63. PubMed ID: 18729327
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of substituted phenyl diaziridines and characterization as mechanism-based inactivators of human cytochrome P450 2B6.
Sridar C; Kobayashi Y; Brevig H; Kent UM; Puppali SG; Rimoldi JM; Hollenberg PF
Drug Metab Dispos; 2006 Nov; 34(11):1849-55. PubMed ID: 16882766
[TBL] [Abstract][Full Text] [Related]
20. Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6.
Lin HL; Zhang H; Hollenberg PF
J Pharmacol Exp Ther; 2009 Apr; 329(1):26-37. PubMed ID: 19168709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
